Yes there are way too many shares outstanding, however I see one of many possible scenarios perhaps playing itself out within the next six months to a year. If FDA approval is given BIEL will then have access to a wide variety of markets that it currently doesn't have, which will mean an exponential increase in revenue, we hope. With this much improved cash flow they could institute a stock buyback program, thus reducing the float and increasing shareholder value. I anticipate this will eventually happen if the projections for revenue materialize as BIEL hopes.
News 
Market Data 
Discover 
AI
